–
The ADHD treatment developer raised $27 million in its IPO in May.
–
Alcobra Pharmaceuticals Ltd. (Nasdaq: ADHD) raised a gross $33 million in its secondary offering on Thursday. The company issued two million shares at $16.50 per share. The underwriters, Stifel Nicolaus, Aegis Capital Corp., JMP Securities have a 30-day option to buy additional 300, 000 shares. Alcobra will use the proceeds for the development of its proprietary drug, MG01CI (Metadoxine extended-release), for the treatment of ADHD and Fragile X Syndrome, a factor in autism.
Alcobra raised $27 million in its IPO in May.
Alcobra’s share price closed at $17.01 on Friday, giving a market cap of $189 million, after falling 0.5% during the session.
Published by www.globes-online.com
1 Comment
Leave a Reply
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
edwartfruitman
March 12, 2015 at 8:22 am
With the rapid increase in cases of ADHD, this issue has
become more of a health crisis. Many psychiatrist
and pharmaceutical companies are working together to find a lasting solution
for this drastic mental disorder.